Will Chiasma, Inc. (CHMA) Short Squeeze Soon? The Stock Formed a Double Bottom Pattern

September 8, 2018 - By Pearl Odom

Chiasma, Inc. (NASDAQ:CHMA) Logo

The chart of Chiasma, Inc. (CHMA) shows a double bottom with $2.23 target or 9.00 % below today’s $2.45 share price. The 7 months chart pattern indicates high risk for the $59.75M company. It was reported on Sep, 8 by Finviz.com. If the $2.23 price target is reached, the company will be worth $5.38 million less. Double bottoms are rare but powerful chart patterns.

The stock increased 4.26% or $0.1 during the last trading session, reaching $2.45. About 63,972 shares traded or 0.52% up from the average. Chiasma, Inc. (NASDAQ:CHMA) has risen 3.33% since September 8, 2017 and is uptrending. It has underperformed by 9.24% the S&P500.

More notable recent Chiasma, Inc. (NASDAQ:CHMA) news were published by: Benzinga.com which released: “55 Biggest Movers From Yesterday” on September 05, 2018, also Benzinga.com with their article: “38 Stocks Moving In Tuesday’s Mid-Day Session” published on September 04, 2018, Nasdaq.com published: “Chiasma to Present at the HC Wainwright 20th Annual Global Investment Conference” on August 29, 2018. More interesting news about Chiasma, Inc. (NASDAQ:CHMA) were released by: Benzinga.com and their article: “33 Stocks Moving In Friday’s Mid-Day Session” published on August 31, 2018 as well as Benzinga.com‘s news article titled: “41 Biggest Movers From Yesterday” with publication date: August 21, 2018.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company has market cap of $59.75 million. The firm offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.